|
| Author/year/country | Population/age/vitamin D level | Intervention | Duration | 25OHD before treatment(g/ml) | 25OHD after treatment (ng/ml) | Hyperandrogenism | Insulin resistance | Dyslipidemia | Inflammation |
|
Seyyed et al., (2017)
Iran [19] | 36 women with PCOS,
aged 20–38 years,
25OHD < 20 ng/ml | G1: 50,000 IU/week of oral vitamin D3 (n = 19);
G2: placebo (n = 17) | 8 weeks | G1: 3.5 ± 4.2;
G2: 9.8 ± 5.1 | 28.24 ± 6.47;
13.3 ± 7.1 | | ↓FPG ↔HOMA-IR,
QUICKI | | |
|
Asemi et al., (2017)
Iran [21] | 104 overweight and obese women with PCOS,
aged 18–40 years,
25OHD < 20 ng/ml | G1: 1000 mg/d calcium + vitamin D placebo (n = 26);
G2: 50,000 IU/week vitamin D + calcium placebo (n = 26);
G3: 1000 mg/d calcium+ 50,000 IU/week vitamin D (n = 26);
G4: calcium placebo + vitamin D placebo (n = 26) | 8 weeks | G1: 13.9 ± 2.0;
G2: 11.6 ± 4.7;
G3: 15.1 ± 3.6;
G4: 14.0 ± 4.1 | 71.2 ± 14.7;
86.8 ± 16.1;
76.4 ± 13.3;
73.5 ± 23.8 | | ↓insulin, HOMA-IR,
↑QUICKI
↔FPG | ↓TG, VLDL-C
↔TC, LDL-C, HDL-C | 8 weeks |
|
Bonakdaran et al., (2012)
Iran [26] | 48 women with PCOS,
aged 20–40 years,
25OHD < 20 ng/ml | G1: 1000 mg/d metformin (n = 17);
G2: 0.5ug/d calcitriol (n = 15);
G3: placebo (n = 16) | 12 weeks | G1:28.2 ± 13.5;
G2:11.4 ± 8.2;
G3:19.9 ± 16.5; | 26.7 ± 10.6;
20.1 ± 16.2;
19.0 ± 15.3 | ↔Total testosterone,
DHEAS | ↔FPG, insulin,
HOMA-IR | | |
|
Foroozanfard et al., (2015)
Iran [22] | 104 overweight women with PCOS who have vitamin D deficiency,
aged 18–40 years,
25OHD < 20 ng/ml | G1: 1000 mg calcium/d plus vitamin D placebo weekly (n = 26);
G2: 50,000 IU/week vitamin D plus calcium placebo daily (n = 26);
G3: 1000 mg/d calcium plus 50,000 IU vitamin D weekly (n = 26);
G4: calcium placebo daily plus vitamin D placebo weekly (n = 26) | 8 weeks | | G1: +0.3 ± 0.4;
G2: +12.5 ± 1.1;
G3: +9.2 ± 1.5;
G4: +0.2 ± 0.6 | | | | ↓hs-CRP |
|
Gupta et al., (2017)
India [27] | 50 women with PCOS,
aged 18–45 years,
25OHD < 30 ng/ml | G1: 12000 IU/week vitamin D (n = 25);
G2: placebo (n = 25) | 12 weeks | G1: 18.56 ± 9.68;
G2: Vacant | 44.90 ± 9.04;
vacant | ↔-Total testosterone,
DHEAS | ↓FPG,
insulin, HOMA-IR
↑ QUICKI | ↔TG, TC,
HDL-C | |
|
Rahimi-Ardabili et al., (2013)
Iran [25] | 50 women with PCOS,
aged 20–40 years,
25OHD < 20 ng/ml | G1: 50,000 IU/20 days of oral cholecalciferol (n = 24);
G2: placebo (n = 26) | 8 weeks | G1:6.9 ± 2.8;
G2:7.28 ± 2.93 | 23.4 ± 6.14;
8.57 ± 3.98 | | | ↓ TC
↔TG, LDL-C, HDL-C,
VLDL-C | ↓hs-CRP |
Javed et al. (2019)
UK [30] | 37 women with PCOS,
aged 18–45 years,
25OHD < 20 ng/ml | G1: 3200IU/day vitamin D (n = 18);
G2: placebo (n = 19) | 12 weeks | G1:10.26 ± 4.57;
G2:12.38 ± 4.45 | 36.22 ± 7.81;
19.07 ± 8.21 | ↔Total testosterone,
SHBG | ↔FPG, insulin,
HOMA-IR | ↔TG, TC, LDL-C,
HDL-C | ↔ hs-CRP |
|
Irani et al., (2015)
USA [31] | 53 women with PCOS,
aged 18–38 years,
25OHD <20 ng/ml | G1: 50,000 IU/week of oral vitamin D3 (n = 35);
G2: placebo (n = 18) | 8 weeks | G1: 16.3 ± 0.9;
G2: 17 ± 1.8 | 43.2 ± 2.4;
17.4 ± 1.9 | ↔Total testosterone,
SHBG | ↔ HOMA-IR | ↓TG
↔HDL-C,
LDL-C | |
|
Maktabi et al., (2017)
Iran [24] | 60 women with PCOS,
aged 18–40 years,
25OHD < 20 ng/ml | G1: 50,000 IU/2 weeks of oral vitamin D3 (n = 30);
G2: placebo (n = 30) | 12 weeks | G1: 12.8 ± 4.5;
G2: 14.5 ± 5.1 | 27.5 ± 9.8;
14.4 ± 5.2 | ↔Total testosterone,
SHBG, DHEAS | ↓FPG, insulin,
HOMA-IR, QUICKI | ↔TG, TC, LDL-C,
HDL-C, VLDL-C | ↓hs-CRP |
|
Jorly Mejia-Montilla et al., (2018)
Venezuela [29] | 169 women with PCOS,
aged 20–40 years,
25OHD < 20 ng/ml | G1: 5000 IU/day vitamin D (n = 84);
G2: placebo (n = 85) | 12 weeks | G1:13.7 ± 4.2;
G2:13.5 ± 4.4 | 19.1 ± 4.9;
13.3 ± 4.5 | | ↓FPG, insulin,
HOMA-IR | ↓TG, TC, LDL-C
↔HDL-C | |
|
Ardabili et al., (2012)
Iran [20] | 50 women with PCOS,
aged 20–40 years,
25OHD < 20 ng/ml | G1:50,000 IU of oral vitamin D3 every 20 days (n = 24);
G2: placebo (n = 26) | 8 weeks | G1: 6.9 ± 2.8;
G2: vacant | 23.4 ± 6.1;
vacant | | ↔FPG, insulin,
HOMA-IR,
QUICKI | | |
|
Jafari-Sfidvajani et al., (2017)
Iran [23] | 56 women with PCOS,
aged 20–40 years,
25OHD < 20 ng/ml | G1: low-calorie diet+ 50,000 IU/week oral vitamin D3 (n = 26);
G2: low-calorie diet + placebo (n = 28) | 12 weeks | G1: 15.83 ± 4.85;
G2: 14.93 ± 5.55 | 43.38 ± 12.61;
25.32 ± 10.13 | ↔Total testosterone,
DHEAS, SHBG | | | |
|
Trummer et al., (2018)
Austria [28] | 123 women with PCOS,
aged ≥ 18 years,
25OHD < 30 ng/ml | G1:20,000 IU of oral vitamin D3/week (n = 81);
G2: placebo (n = 42) | 24 weeks | G1: 19.55 ± 6.73;
G2: 19.55 ± 7.01 | 36.14 ± 8.05;
22.76 ± 11.82 | ↔Total testosterone | ↔ FPG, HOMA-IR,
QUICKI | ↔TG, TC | |
|
